Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder
DRKS00024066Phase 3Not yet recruiting
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in binge eating disorder (BED) comparing ERP plus hydrocortisone with ERP plus placebo (2 arms). Planned start Feb 2022; status: not yet recruiting.
02
Drugs
hydrocortisone
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on DRKS00024066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00024066.